Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
OK

NASDAQ · OKUR

OnKure Therapeutics, Inc.

Healthcare · Biotechnology

$2.50

Up+$0.09 (+3.60%)

Updated Nov 5, 2026, 12:06 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
44.44M
P/E ratio
-6.67
Dividend yield
0.00%
52-week range
$2.01 – $5.38
Volume
220.07K
Avg. volume
131.89K

Price performance · OKUR

OKUR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

OKUR closed at $2.50 after 20 trading sessions, up 6.38% for the selected period.

Last close
$2.50
Period change
+6.38%
Period low
$2.10
Period high
$2.63
Daily close
View OHLC price history
OKUR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$2.60$2.60$2.44$2.50220.07K
Nov 2, 2026$2.64$2.72$2.47$2.59500.84K
Oct 30, 2026$2.61$2.67$2.53$2.62306.76K
Oct 29, 2026$2.63$2.68$2.44$2.62427.59K
Oct 28, 2026$2.56$2.661$2.46$2.63282.59K
Oct 27, 2026$2.49$2.72$2.475$2.595320.24K
Oct 26, 2026$2.59$2.625$2.38$2.475258.09K
Oct 23, 2026$2.62$2.62$2.48$2.52240.86K
Oct 22, 2026$2.30$2.59$2.28$2.58243.94K
Oct 21, 2026$2.37$2.40$2.25$2.30232.76K
Oct 20, 2026$2.25$2.475$2.25$2.36235.15K
Oct 19, 2026$2.10$2.26$2.02$2.25501.47K
Oct 16, 2026$2.14$2.14$2.01$2.10386K
Oct 15, 2026$2.26$2.28$2.09$2.13349.91K
Oct 14, 2026$2.29$2.38$2.21$2.25381.17K
Oct 13, 2026$2.40$2.40$2.31$2.345232.55K
Oct 12, 2026$2.41$2.47$2.40$2.42146.43K
Oct 9, 2026$2.29$2.42$2.23$2.41609.37K
Oct 8, 2026$2.34$2.4558$2.13$2.30519.58K
Oct 7, 2026$2.41$2.46$2.30$2.35260.72K

Latest OKUR news

The latest Smart Investors Daily articles mentioning OKUR.

Stock researchCompany · Overview

OKUR research

Overview

Company profile and research snapshot.

Company profile

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$35.00
Implied upside
—
Analysts
—
OKUR recent ratings
DateFirmRatingTarget
Aug 14, 2026OppenheimerOutperform—
Jul 20, 2026HC Wainwright & Co.Buy—
Mar 16, 2026HC Wainwright & Co.Buy—
Aug 26, 2025HC Wainwright & Co.Buy—
Mar 18, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference

BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference being held in New York on September 14 – 16, 2026. The OnKure management team will host one-on-one meetings during the conference. Interested investors should contact their Morgan

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By